



Myotonic dystrophy: Emerging mechanisms for DM1 and DM2

Diane H. Cho, Stephen J. Tapscott

► To cite this version:

Diane H. Cho, Stephen J. Tapscott. Myotonic dystrophy: Emerging mechanisms for DM1 and DM2. *Biochimica et Biophysica Acta - Molecular Basis of Disease*, 2007, 1772 (2), pp.195. 10.1016/j.bbadis.2006.05.013 . hal-00562719

HAL Id: hal-00562719

<https://hal.science/hal-00562719>

Submitted on 4 Feb 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Accepted Manuscript


Myotonic dystrophy: Emerging mechanisms for DM1 and DM2

Diane H. Cho, Stephen J. Tapscott

PII: S0925-4439(06)00098-6
DOI: doi:[10.1016/j.bbadis.2006.05.013](https://doi.org/10.1016/j.bbadis.2006.05.013)
Reference: BBADIS 62584

To appear in: *BBA - Molecular Basis of Disease*

Received date: 3 April 2006
Revised date: 26 May 2006
Accepted date: 26 May 2006



Cite this article as: Diane H. Cho, Stephen J. Tapscott, Myotonic dystrophy: Emerging mechanisms for DM1 and DM2, *BBA - Molecular Basis of Disease* (2006), doi:[10.1016/j.bbadis.2006.05.013](https://doi.org/10.1016/j.bbadis.2006.05.013)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Myotonic Dystrophy: Emerging Mechanisms for DM1 and DM2

Diane H. Cho^{1,2}, Stephen J. Tapscott^{1,2,3}

1. Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA

2. Paul D. Wellstone Muscular Dystrophy Cooperative Research Center, Seattle, WA

3. Corresponding author

Stephen J. Tapscott

Fred Hutchinson Cancer Research Center

Mailstop C3-168

1100 Fairview Avenue North

Seattle, WA 98109-1024

Ph: 206-667-4499

FAX: 206-667-6524

email: stapscot@fhcrc.org

Keywords: myotonic dystrophy; repeat expansion; DMPK; ZNF9; MBNL; CUG-BP

ABSTRACT

Myotonic dystrophy (DM) is a complex multisystemic disorder linked to two different genetic loci. Myotonic dystrophy type 1 (DM1) is caused by an expansion of a CTG repeat located in the 3' untranslated region (UTR) of *DMPK* (myotonic dystrophy protein kinase) on chromosome 19q13.3. Myotonic dystrophy type 2 (DM2) is caused by an unstable CCTG repeat in intron 1 of *ZNF9* (zinc finger protein 9) on chromosome 3q21. Therefore, both DM1 and DM2 are caused by a repeat expansion in a region transcribed into RNA but not translated into protein. The discovery that these two distinct mutations cause largely similar clinical syndromes put emphasis on the molecular properties they have in common, namely, RNA transcripts containing expanded, non-translated repeats. The mutant RNA transcripts of DM1 and DM2 aberrantly affect the splicing of the same target RNAs, such as chloride channel 1 (CLIC-1) and insulin receptor (INSR), resulting in their shared myotonia and insulin resistance. Whether the entire disease pathology of DM1 and DM2 is caused by interference in RNA processing remains to be seen. This review focuses on the molecular significance of the similarities and differences between DM1 and DM2 in understanding the disease pathology of myotonic dystrophy.

INTRODUCTION

Overview of Repeat Expansion Disorders

Myotonic dystrophy is currently one of over 30 neurological disorders that can attribute their pathogenesis to extensions of tandem repeats above a critical size. Yet the theories as to how large repeat arrays can cause such highly variable and multifaceted diseases are numerous and unresolved [1]. In general, the repeats become meiotically unstable above a certain pathogenic size threshold, and often demonstrate tissue-specific somatic mosaicism of increasing repeat lengths over time. Many of the disorders also show a clear propensity for inheritance of a more severe disease phenotype with increasing penetrance than previous generations, termed anticipation [2, 3]. Most of the expansion disorders exhibit a delayed onset form of their diseases, indicating that they may share mechanisms that postpone clinical expression until later in life. The population maintenance of these disorders marked by low reproductive fitness also indicates that there might be a common mechanism of generating new expansions from an existing pool of normal size repeats [4, 5]. Lastly, nuclear inclusions typically characterize repeat expansion disorders, but they begin to differ by whether these aberrant aggregations are derived from mutant protein or RNA transcripts.

Depending on where the unstable repeats are located within the gene, the repeat expansion disorders can be classified as having coding or noncoding mutations. Coincidentally, in 1991, the first two triplet repeat expansion disorders discovered revealed examples from both coding and noncoding categories – the fragile X syndrome was linked to unstable CGG repeats in the noncoding 5'UTR of *FMRI* [6-8], whereas spinobulbar muscular atrophy was associated with unstable CAG repeats in the coding region of *AR* [9]. DM1 followed in 1992 as the third trinucleotide repeat expansion disorder discovered and was mapped to CTG repeats in the noncoding 3'UTR of *DMPK* [10-13]. Coding region expansion disorders such as Huntington's disease (HD), dentatorubralpallidolusian atrophy (DRPLA), and spinocerebellar ataxia (SCA) 1, 2, 3, 6, 7, and 17, are comprised of CAG repeats that become translated into polyglutamine tracts. Polyglutamine extensions from 40-100 residues become toxic to cells of the central nervous system [14]. Noncoding triplet repeat expansion diseases such as

in SCA8, fragile X syndrome, and Friedreich ataxia encode tandem CTG, CGG or GAA repeat units, respectively [15, 16]. Diseases caused by noncoding repeats exhibit a higher range of pathogenic repeat lengths, often numbering in the hundreds or thousands of repeats.

Unlike the gain-of-function mutations of the altered protein products from the polyglutamine expansion disorders, the noncoding expansion disorders appear to result from either a loss-of-function by transcriptional repression or a gain-of-function mediated by the mutant RNA transcripts. For example, hypermethylation of the expanded CGG repeat region in the 5'UTR of *FMRI* silences expression of the gene [17-19]. In agreement with the loss-of-function model, mice deficient in *Fmr1* display a similar reduction in cognitive abilities as humans with fragile X syndrome [20]. In contrast, both DM1 and SCA8 express RNA with untranslated CTG repeats in the 3'UTR domains of their respective genes. The fact that SCA8 is predicted to be a noncoding RNA highlights how protein function of the mutant genes may not be primarily involved in mediating these particular disorders. It is, however, studies on myotonic dystrophy that has first unveiled the critical role of RNA in contributing to disease phenotype.

Myotonic Dystrophy

Myotonic dystrophy (Steinert's disease, 1909) is the most prevalent form of muscular dystrophy with a frequency of 1 in 8000 individuals worldwide [21]. Affected individuals express highly heterogeneous, multisystemic symptoms including myotonia (muscle hyperexcitability), progressive muscle weakness and wasting, cataract development, testicular atrophy, and cardiac conduction defects [22, 23]. It has an autosomal dominant mode of inheritance and disease severity generally correlates with repeat length. The first insight into the molecular mechanism of this disorder came from its linkage to chromosome 19q13.3 and subsequent identification of an expanded CTG repeat in the 3' UTR of *DMPK* in patients with DM1. Wildtype individuals have 5-38 CTG repeats at this locus, whereas individuals with DM1 have repeats in the hundreds to thousands [24].

Once the genetic mutation for DM1 was identified, it became clear that there was a subset of DM patients who did not have CTG expansions at the DM1 locus, but did share significant clinical aspects of the disease, including an autosomal dominant mode of inheritance, myopathy, myotonia, cataracts, and cardiac disturbances [25, 26]. The early pattern of muscle weakness was proximal in these patients, often involving hip flexors and extensors, which initially distinguished them from DM1 patients who displayed an early pattern of distal muscle weakness, such as those of the face, neck and fingers [27, 28]. Hence, proximal myotonic myopathy (PROMM) was the initial term for those who did not have DM1 [26]. Manual strength tests, however, showed that PROMM patients also shared early patterns of muscle weakness in the distal neck and finger flexors, but in a less prominent manner than DM1 [27, 29]. As the disease progresses, the muscle degeneration pattern may overlap and reach proximal and distal muscles for DM1 and DM2, respectively [30]. Almost a decade after the discovery of unstable CTG repeats in 3' UTR of *DMPK*, Liquori et al. revealed that a CCTG expansion in intron 1 of *ZNF9* on chromosome 3q21 is associated with individuals who were diagnosed with having PROMM/DM2 [31]. This new locus associated with the myotonic dystrophy disorder has been designated as DM2. The frequency of DM2 is uncertain, but most recent reports suggest that its incidence could be as high as DM1 [32].

Both DM1 and DM2 share repeat expansions in noncoding regions of genes (*DMPK* and *ZNF9*) that are expressed in tissues affected by this disease. *DMPK*, a serine-threonine kinase [3, 13], shows no functional similarity to *ZNF9*, a 7 zinc finger protein thought to bind RNA [33-35]. The fact that both genes were associated by repeat expansions in transcribed but untranslated regions suggested that the mutant RNA might have a significant role in the disease process. However, a key difference between DM1 and DM2 is that only the DM1 locus presents a congenital form of this disorder not shared by DM2 [23, 36]. This strongly implies that although the basic features of adult and congenital DM may stem from the transcription of expanded CUG/CCUG repeats, regardless of the encoding gene, additional qualities unique to early onset DM1 may be ascribed to changes at the DM1 locus.

Clinical Features of DM1 and DM2

DM1 and DM2 manifest signs of myotonia, muscle weakness, and early cataract development as the principal traits of myotonic dystrophy [27, 30, 37]. Changes in chloride conductance from defects in CIC-1 protein function account for the myotonia observed in most symptomatic adults [38, 39]. Its accompaniment with progressive muscle degeneration distinguishes this disorder from other forms of clinical myotonias. Although the initial pattern of muscle weakness is noticeably different between DM1 and DM2 (distal vs proximal), the muscle biopsies show a similar histology of central nucleation and increased fiber sizes. Muscle atrophy, as shown by ATPase staining, occurs preferentially in type 1 fibers in DM1 and in type 2 fibers in DM2 [40]. The most treatable symptom of DM is cataract development beginning in the second decade or later and is characterized by multicolored lens opacities on slit-lamp examination. Additional common features include testicular atrophy, frontal balding, insulin insensitivity and hypogammaglobulinemia (reduced IgG and IgM serum levels). Cardiac problems typified by varied and potentially lethal arrhythmias and occasional signs of cardiomyopathy, are additional examples of the multisystemic nature of this disease [37].

DM2 is considered to present a milder version of this disorder compared to DM1 in most aspects of their related clinical phenotypes although the CCTG expansions can be much larger than DM1 ranging in size from 75 to 11,000 repeats [31] (Fig. 1). In addition, there is no strong evidence for anticipation in DM2 as there is in DM1, in which successive generations inherit increasing disease severity with decreasing age of onset [29]. Most of the clinical features of DM2 appear in adulthood (median age 48 yrs) [29] as opposed to DM1 that clearly demonstrates adult-onset, childhood-onset and congenital forms with corresponding increasing disease severity and repeat size. The most significant difference between DM1 and DM2 is the presence of the congenital form of DM (hereafter referred to as congenital DM1) that is absent in DM2. Neonatal symptoms of congenital DM1 do not include some of the features characteristic of adult onset DM1 and DM2, such as cataract development, myotonia and myopathy [41]. Instead, congenital DM1 is associated with hypotonia, mental retardation, facial diplegia and a maternal bias in DM transmission [36, 42, 43]. And rather

than progressive muscle degeneration, congenital DM1 exhibits skeletal muscle immaturity that makes this early onset form of DM1 distinct from the adult-onset examples of DM1 and DM2 [44, 45]. To a somewhat lesser degree, childhood-onset in DM1 also exhibits cognitive impairment without the maternal bias in transmission seen in congenital DM1 [23, 46]. Although there are a few reports of childhood-onset in DM2, they are not usually associated the developmental disease of the central nervous system as in congenital and childhood-onset DM1. Surviving congenital and childhood-onset DM1 patients eventually manifest the hallmark features of the adult-onset form of the disorder. The clinical complexity produced by dynamic mutations from two different loci engendered diverse models for the pathobiology of this expansion disorder.

Model Mechanisms for Myotonic Dystrophy

There are several theories as to the molecular pathophysiology of DM1 [47]. In all, the expanded CTG repeats are proposed to disrupt normal cellular processes at the RNA, protein or chromatin level. Initial research targeted the role of the DMPK protein, especially in light of the fact that several studies showed that cytoplasmic DMPK was reduced in DM1 patients, presumably due to the deleterious effects of the expanded repeats on RNA processing or nucleocytoplasmic transport [48-50]. To test that haploinsufficiency of DMPK may elicit signs of myotonic dystrophy, two groups eliminated its function in mice and demonstrated that mice homozygous for the DMPK deletion developed a late onset mild myopathy [51, 52]. Mice both heterozygous and homozygous for the disrupted DMPK gene also displayed cardiac conduction defects [53]. In addition, skeletal muscle cells and cardiac myocytes isolated from heterozygous and homozygous DMPK-deficient mice exhibited abnormalities in Na⁺ channel gating and Ca²⁺ cycling akin to DM1 patients, which implicated DMPK in muscle weakness and cardiac dysfunction through its involvement in ion homeostasis [54, 55]. The mild and partial DM phenotype observed in the DMPK knockout mice also indicated that other models were necessary to fully explain the complex disease phenomenon.

There is strong corroboration for the hypothesis that DM is primarily an RNA-mediated disease (Fig. 2). Initial studies into the intracellular distribution of DMPK transcripts surprisingly revealed that DM1 cells were associated with multiple nuclear foci of mutant DMPK RNA [56]. This visual cue led to the novel theory that the ribonuclear inclusions signify a toxic gain-of-function effect mediated at the RNA level [57, 58]. In search of proteins that bind to the anomalous triplet repeat expansion, *in vitro* studies identified CUG-binding protein (CUG-BP1), which belongs to the CELF (CUG-BP1 and ETR-3-like factors) family of proteins [59-61]. A major insight into the cellular process that might be impaired in myotonic dystrophy came from the discovery that CUG-BP1 regulates alternative splicing of cardiac troponin T (TNNT2) pre-mRNA by directly binding to CUG-repeat-containing splicing enhancers within the transcript, and that this splicing pattern was disrupted in DM1 cardiac and skeletal muscle tissues [62]. There were inconsistencies in trying to fit CUG-BP1 into the emerging model that the trans-dominant effects of the mutant RNA is mediated by the sequestration and inactivation of RNA binding proteins within the intranuclear inclusions found in DM1 cells. The aberrant splicing of TNNT2 indicated that CUG-BP1 activity was increased in DM1, rather than decreased by its titration away from its normal function. Studies also failed to demonstrate co-localization of CUG-BP1 with the foci of mutant DMPK RNA, bringing to question whether CUG-BP1 plays a secondary, rather than primary role in the RNA pathogenesis of DM1 [63, 64]. In the meantime, it became evident that increased CUG-BP1 levels in DM1 myoblasts [65] were involved in the aberrant splicing of additional genes such as CIC-1 and INSR, leading to the clinical symptoms of myotonia and insulin resistance, respectively [66, 67]. Moreover, transgenic mice engineered to express 250-300 noncoding CUG repeats in the context of either the human skeletal actin gene (HSA^{LR}) or the human *DMPK* gene developed ribonuclear inclusions, myotonia, myopathy, and CIC-1 splicing defects which emphasized the primary role of the mutant RNA on disease pathogenesis [68, 69].

Further investigation into proteins that bind to CUG sequences revealed a family of MBNL (muscleblind-like) proteins that bind specifically to the double-stranded RNA hairpins formed by long

stretches of CUG repeats [70]. All three isoforms of MBNL proteins (MBNL1, MBNL2, MBNL3) were recruited to the mutant RNA foci in DM1 cells, presumably diverting them from their normal cellular functions [71]. Since the *Drosophila muscleblind* homolog is critical for terminal differentiation in muscle and photoreceptor cells [72, 73], MBNL proteins became attractive candidates for the toxic effects of mutant RNA in the pathology of DM1. This trans-dominant RNA theory was further substantiated by the fact that mice homozygous for Mbnl1 deficiency (Mbnl1^{Δ3/Δ3}) developed myotonia, cataracts and splicing irregularities in CIC-1, TNNT2, and skeletal muscle troponin T (TNNT3) which are phenotypic and molecular changes associated with DM1 [74]. Interestingly, it was shown that the splicing activities of MBNL proteins and CUG-BP1 are antagonistic, with MBNL proteins promoting a switch to adult isoforms and CUG-BP1 inducing retention of embryonic isoforms of genes mis-regulated in DM1 tissues such as INSR and TNNT2 [75]. Although their splicing functions are in opposition to one another, MBNL1/MBNL2 and CUG-BP1 do not directly compete with each other as they require different RNA binding sites on their target pre-mRNAs, and their expression levels are independently regulated [76]. Accordingly, transgenic mice overexpressing CUG-BP1 developed signs of muscle defects and abnormal splicing of CIC-1 and TNNT2 similar to Mbnl1^{Δ3/Δ3} mice [77, 78]. Cell culture studies using minigenes and siRNA depletion of MBNL1/MBNL2 or CUG-BP1 indicate that focal accumulation of mutant CUG RNA is primarily dependent on MBNL1, but the aberrant splicing of TNNT2 and INSR genes require CUG-BP1 binding sites [62, 67, 75]. In addition, nuclear aggregation of MBNL1 with expanded CAG repeats instead of CUG repeats does not correlate with splicing irregularities [79], bringing to question the extent of involvement of parallel processes mediated by MBNL sequestration and CUG-BP1 elevation in DM1 pathogenesis. Additional research will be needed to clarify the exact mechanism by which MBNL1 is functionally inhibited by the CUG repeats, and apparently not by the CAG repeats, and the mechanism of increasing CUG-BP1 expression and activity in DM1.

In addition to the major role of the CUG repeat containing RNA, the chromatin landscape surrounding the pathological repeat motif may contribute to the disease by affecting the expression of

neighboring genes at the DM1 locus. CTG repeats were shown to be strong nucleosome positioning elements [80, 81], and the expansion of the CTG repeats at the DM1 locus resulted in the occlusion of an adjacent DNase hypersensitive site, signifying a fundamental change in chromatin structure that extends beyond the repetitive sequence motif upon repeat expansion [82]. DMPK is located in a gene-rich region, surrounded by genes less than a kilobase away on either side such as DMWD (dystrophia myotonica-containing WD repeat motif) upstream of its 5'UTR, and SIX5 (sine oculis homeobox homolog 5, formerly DMAHP) immediately downstream of its 3'UTR. Other genes such as RSHL1 (radial spoke head-like) and SYMPLEKIN are all included in a 120kb region that is flanked by nuclear matrix attachment regions (MARs) that place DMPK and regional genes in the same chromatin fiber loop [83]. The loss of a DNase hypersensitive site located between the CTG repeats in DMPK's 3'UTR and SIX5's promoter on the mutant DMPK allele suggested that this normally 'open' chromatin region becomes 'closed' when the triplet repeats expand, making it less accessible to DNA binding factors for gene regulation. Reporter assays and allele-specific RT-PCRs demonstrated that this normally nuclease-sensitive region contains an enhancer to SIX5, called the hypersensitive site-enhancer (HSE), and that the loss of the HSE associated by the altered chromatin structure caused by the expanded repeat results in suppression of SIX5 from the expanded DMPK allele in human DM1 cells [84, 85]. To test that loss of SIX5 expression contributes to the DM1 disease phenotype, SIX5-deficient mice were created by two groups. With increasing severity, heterozygous and homozygous mice for SIX5 deletion developed premature cataracts [86, 87]. In a similar dose-dependent manner, loss of SIX5 also resulted in cardiac conduction defects and testicular atrophy [88, 89]. With additional evidence that DMWD expression from the mutant allele is also decreased in human DM1 cells [90], it became plausible to suspect that some of the features associated with DM1 might be instigated by repeat expansion-induced chromatin condensation and suppression of local DM1 genes.

In the midst of accumulating evidence for the proposed DMPK haploinsufficiency, trans-dominant RNA, and regional chromatin condensation models to varying degrees, the existence of another DM2 locus associated with the disorder promised to impart more insight into its molecular pathology, and

perhaps provide more validity to one theory over the others. When DM2 was identified as a CCTG expansion in intron 1 of *ZNF9* associated with nuclear inclusions composed of mutant ZNF9 transcripts and MBNL proteins, it reinforced the primacy of the RNA toxic gain-of-function hypothesis [31, 91]. Furthermore, alternatively spliced isoforms of CIC-1 and INSR found in DM1 cells were also found in DM2 tissues, implying that similar pathogenic mechanisms were initiated by expanded CUG or CCUG RNA repeats [92, 93]. However, an important difference between DM1 and DM2 that might not be explained solely by the toxicity of repetitive elements in RNA, is that only the DM1 locus presents a congenital form with symptoms of mental retardation and hypotonia not shared by DM2. And rather than progressive muscle degeneration, congenital DM1 exhibits muscle immaturity akin to cell culture studies demonstrating inhibition of myogenesis by overexpression of the 3'UTR region of DMPK [94]. This suggests that congenital DM1 might be caused by factors associated with the DM1 locus that add additional pathological mechanisms to those mediated by the CUG containing RNA through MBNL proteins and CUG-BP1 in adult-onset DM1 and DM2.

DM1 Locus and associated congenital DM1

Repetitive elements exist throughout the human genome and are susceptible to epigenetic processes such as bidirectional transcription, histone modification and DNA methylation [95-98]. Congenital DM1 provides evidence for all of the above alterations at the DM1 locus that may have important implications for the unique developmental and clinical manifestation of this disease and perhaps other repeat expansion disorders. Cell culture studies in C2C12 myoblasts demonstrated that stable expression of mutant CUG₁₀₀ RNA generates foci, but does not inhibit myoblast differentiation in the same manner as expressing DMPK's 3'UTR with expanded repeats [99]. Cis-elements adjacent to the repeat domain in DMPK's 3'UTR were thus found necessary for impairing muscle differentiation in C2C12 cells [94, 100]. Transgenic mice designed to overexpress the human DMPK 3'UTR with a wildtype number of repeats demonstrated myogenic defects, including reduced fusion potential in primary myoblasts that resembled the delayed muscle development profile of congenital

DM1 [101]. In all, influences other than CUG repeats expressed at the RNA level may contribute to congenital DM1 and those factors may involve properties of the DM1 locus.

Prior studies have shown that the CTG repeats in *DMPK* are flanked by CTCF sites [83] that can function as insulators to the effects of nearby enhancers or to the position effects of suppressive chromatin domains [102]. Interestingly, CTCF binding is inhibited by CpG methylation that occurs in an area encompassing the CTG repeats in congenital DM1 and not adult DM1 [83, 103]. Further studies have shown that CTCF binding is indeed absent on the expanded, methylated DM1 allele, but present on the wildtype, non-methylated allele in a congenital DM1 cell line [104]. A model for heterochromatin formation at repetitive DNA sequences implicates dsRNA in triggering an RNAi pathway that produces siRNAs, recruits histone methyltransferases, heterochromatin protein 1 (HP1) and DNA methyltransferases [105]. In comparing the wildtype and expanded alleles in congenital DM1, it was shown that bidirectional transcription extends across the CTG repeats and is converted to siRNA-sized fragments on both alleles, but the antisense transcription is limited by the presence of CTCF on the wildtype allele. On the wild-type allele, this was associated with heterochromatin-associated modifications restricted to the region of the repeat, whereas the functional loss of CTCF next to the expanded repeats was correlated with the spread of antisense transcription and heterochromatin-associated histone modifications to the surrounding regions, which might account for the loss of the nearby HSE and reduced *SIX5* expression [104]. Exclusion of CTCF insulator activity on the expanded allele might also expose the *DMPK* promoter to the enhancer activity of *SIX5*'s HSE during embryogenesis when it is most active [86], potentially resulting in elevated levels of expanded *DMPK* RNA. As shown in cell culture and transgenic mouse studies, increased expression of *DMPK* results in signs of arrested muscle development and other DM1-associated pathologies that is aggravated by but not dependent on expanded CUG repeats [101, 106]. It is currently unknown whether the DM2 locus shares similar chromatin features as DM1.

HSA^{LR} and *Mbn11*^{Δ3/Δ3} mice connect DM1 and DM2 pathogenesis to the RNA toxic gain-of-function hypothesis but fail to demonstrate the congenital form of this disease. More recently, two

groups have shown that overexpressing CUG-BP1 in skeletal muscle of mice leads to neonatal lethality at doses from 4 to 10 fold above endogenous levels [77, 78]. Histological analysis of skeletal muscle from the CUG-BP1 transgenic mice also revealed defects in myogenic development that was partly characteristic of congenital DM1. The CUG-BP1 transgenic mice displayed DM1-associated splicing defects for *Clcn1*, and cardiac troponin T (*Tnnt2*), in addition to myotubularin-related 1 gene (*Mtmr1*). Although MTMR1 splicing irregularities have not been tested in adult DM1 and DM2 skeletal muscle, it has been shown that MTMR1 is aberrantly spliced in congenital DM1 muscle cell cultures and tissue samples [107], which suggests that the congenital phenotype of this expansion disorder may also result from mis-regulation in alternative splicing through the antagonistic roles of MBNL proteins and CUG-BP1. Mental retardation distinguishes congenital myotonic dystrophy from adult DM1 and DM2, but there have been no reports of CNS involvement in *Mbn1*^{Δ3/Δ3} mice where *Mbn1* function in brains is eliminated. However, transgenic mice overexpressing human DMPK with expanded repeats does lead to altered tau protein isoforms in neurons [69]. Similarly, studies on adult DM1 brain tissues demonstrated ribonuclear inclusions of mutant DMPK RNA and MBNL proteins, as well as splicing alterations in neuronal pre-mRNAs such as NMDA NR1 receptor (*NMDAR1*), amyloid beta precursor protein (*APP*), and microtubule-associated protein tau (*MAPT*) [108]. It remains to be seen whether congenital DM1 is also associated with comparable ribonuclear inclusions and compromises in alternative splicing in the CNS.

Conclusions and Future Therapies

As the molecular intricacies of myotonic dystrophy continue to unfold, it is now clear that unstable expansions of CTG or CCTG repeats from genetically distinct contexts can cause this disease syndrome. There is also no doubt that expression of RNA transcripts containing pathogenic repeat lengths can produce defects in alternative splicing of multiple RNAs, providing a basis for the multisystemic features of DM1 and DM2. Therapies targeted to diminishing the toxic effects of CUG repeats show potential in ameliorating the debilitating aspects of this disease. For example, exploiting

the endogenous RNAi pathway has been successful in reducing the nuclear accumulation of expanded RNA foci [109, 110], and even restoring CUG-BP1 levels and repairing muscle differentiation and insulin insensitivity defects in DM1 myoblasts [111]. Also, catalyzing the cleavage of DMPK RNA in DM1 myoblasts by a hammerhead ribozyme demonstrates a similar reduction in nuclear foci and rescue of INSR splicing alterations [112]. Finally, a survey of chemical compounds to alleviate the toxic effects of expanded CTG repeats in a neuronal cell culture model shows promise in using flavonoids and DHEA-S by an unknown mechanism [113]. There are other prospective targets for therapy such as MBNL proteins, CUG-BP1, and certain transcription factors that may also be sequestered by the expanded RNA transcripts [114]. It is a lasting tribute to the many researchers who have labored to reveal the molecular mechanisms that cause DM1 and DM2 that rational therapies are being developed that will surely ameliorate or cure these diseases.

ACKNOWLEDGEMENTS

SJT and DHC were supported by NIH AR4203 and AR050741.

REFERENCES

- [1] J.R. Gatchel, H.Y. Zoghbi, Diseases of unstable repeat expansion: mechanisms and common principles, *Nat Rev Genet* 6 (2005) 743-755.
- [2] C.E. Pearson, K.N. Edamura, J.D. Cleary, Repeat instability: mechanisms of dynamic mutations, *Nat Rev Genet* 6 (2005) 729-742.
- [3] P. Groenen, B. Wieringa, Expanding complexity in myotonic dystrophy, *Bioessays* 20 (1998) 901-912.
- [4] R.D. Wells, S.T. Warren, M. Sarmiento, Genetic instabilities and hereditary neurological diseases, Academic Press, San Diego, Calif., 1998.
- [5] R. Chakraborty, D.N. Stivers, R. Deka, L.M. Yu, M.D. Shriver, R.E. Ferrell, Segregation distortion of the CTG repeats at the myotonic dystrophy locus, *Am J Hum Genet* 59 (1996) 109-118.
- [6] Y.H. Fu, D.P. Kuhl, A. Pizzuti, M. Pieretti, J.S. Sutcliffe, S. Richards, A.J. Verkerk, J.J. Holden, R.G. Fenwick, Jr., S.T. Warren, et al., Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox, *Cell* 67 (1991) 1047-1058.
- [7] E.J. Kremer, M. Pritchard, M. Lynch, S. Yu, K. Holman, E. Baker, S.T. Warren, D. Schlessinger, G.R. Sutherland, R.I. Richards, Mapping of DNA instability at the fragile X to a trinucleotide repeat sequence p(CCG)_n, *Science* 252 (1991) 1711-1714.
- [8] A.J. Verkerk, M. Pieretti, J.S. Sutcliffe, Y.H. Fu, D.P. Kuhl, A. Pizzuti, O. Reiner, S. Richards, M.F. Victoria, F.P. Zhang, et al., Identification of a gene (FMR-1) containing a CGG repeat

- coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome, *Cell* 65 (1991) 905-914.
- [9] A.R. La Spada, E.M. Wilson, D.B. Lubahn, A.E. Harding, K.H. Fischbeck, Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy, *Nature* 352 (1991) 77-79.
- [10] J. Buxton, P. Shelbourne, J. Davies, C. Jones, T. Van Tongeren, C. Aslanidis, P. de Jong, G. Jansen, M. Anvret, B. Riley, et al., Detection of an unstable fragment of DNA specific to individuals with myotonic dystrophy, *Nature* 355 (1992) 547-548.
- [11] Y.H. Fu, A. Pizzuti, R.G. Fenwick, Jr., J. King, S. Rajnarayan, P.W. Dunne, J. Dubel, G.A. Nasser, T. Ashizawa, P. de Jong, et al., An unstable triplet repeat in a gene related to myotonic muscular dystrophy, *Science* 255 (1992) 1256-1258.
- [12] M. Mahadevan, C. Tsilfidis, L. Sabourin, G. Shutler, C. Amemiya, G. Jansen, C. Neville, M. Narang, J. Barcelo, K. O'Hoy, et al., Myotonic dystrophy mutation: an unstable CTG repeat in the 3' untranslated region of the gene, *Science* 255 (1992) 1253-1255.
- [13] J.D. Brook, M.E. McCurrach, H.G. Harley, A.J. Buckler, D. Church, H. Aburatani, K. Hunter, V.P. Stanton, J.P. Thirion, T. Hudson, et al., Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member, *Cell* 68 (1992) 799-808.
- [14] C.M. Everett, N.W. Wood, Trinucleotide repeats and neurodegenerative disease, *Brain* 127 (2004) 2385-2405.
- [15] M.D. Koob, M.L. Moseley, L.J. Schut, K.A. Benzow, T.D. Bird, J.W. Day, L.P. Ranum, An untranslated CTG expansion causes a novel form of spinocerebellar ataxia (SCA8), *Nat Genet* 21 (1999) 379-384.
- [16] L.T. Timchenko, C.T. Caskey, Triplet repeat disorders: discussion of molecular mechanisms, *Cell Mol Life Sci* 55 (1999) 1432-1447.
- [17] M. Pieretti, F.P. Zhang, Y.H. Fu, S.T. Warren, B.A. Oostra, C.T. Caskey, D.L. Nelson, Absence of expression of the FMR-1 gene in fragile X syndrome, *Cell* 66 (1991) 817-822.
- [18] J.S. Sutcliffe, D.L. Nelson, F. Zhang, M. Pieretti, C.T. Caskey, D. Saxe, S.T. Warren, DNA methylation represses FMR-1 transcription in fragile X syndrome, *Hum Mol Genet* 1 (1992) 397-400.
- [19] M.V. Bell, M.C. Hirst, Y. Nakahori, R.N. MacKinnon, A. Roche, T.J. Flint, P.A. Jacobs, N. Tommerup, L. Tranebjaerg, U. Froster-Iskenius, et al., Physical mapping across the fragile X: hypermethylation and clinical expression of the fragile X syndrome, *Cell* 64 (1991) 861-866.
- [20] Fmr1 knockout mice: a model to study fragile X mental retardation. The Dutch-Belgian Fragile X Consortium, *Cell* 78 (1994) 23-33.
- [21] P.S. Harper, *Myotonic dystrophy*, 2nd ed., W.B. Saunders, London; Philadelphia, 1989.
- [22] L. Machuca-Tzili, D. Brook, D. Hilton-Jones, *Clinical and molecular aspects of the myotonic dystrophies: a review*, *Muscle Nerve* 32 (2005) 1-18.
- [23] P.S. Harper, *Myotonic dystrophy: present management, future therapy*, Oxford University Press, Oxford; New York, 2004.
- [24] C. Zerylnick, A. Torroni, S.L. Sherman, S.T. Warren, Normal variation at the myotonic dystrophy locus in global human populations, *Am J Hum Genet* 56 (1995) 123-130.
- [25] C.A. Thornton, R.C. Griggs, R.T. Moxley, 3rd, Myotonic dystrophy with no trinucleotide repeat expansion, *Ann Neurol* 35 (1994) 269-272.
- [26] K. Ricker, M.C. Koch, F. Lehmann-Horn, D. Pongratz, M. Otto, R. Heine, R.T. Moxley, 3rd, Proximal myotonic myopathy: a new dominant disorder with myotonia, muscle weakness, and cataracts, *Neurology* 44 (1994) 1448-1452.
- [27] G. Meola, R.T. Moxley, 3rd, Myotonic dystrophy type 2 and related myotonic disorders, *J Neurol* 251 (2004) 1173-1182.
- [28] K. Ricker, M.C. Koch, F. Lehmann-Horn, D. Pongratz, N. Speich, K. Reiners, C. Schneider, R.T. Moxley, 3rd, Proximal myotonic myopathy. Clinical features of a multisystem disorder similar to myotonic dystrophy, *Arch Neurol* 52 (1995) 25-31.

- [29] J.W. Day, K. Ricker, J.F. Jacobsen, L.J. Rasmussen, K.A. Dick, W. Kress, C. Schneider, M.C. Koch, G.J. Beilman, A.R. Harrison, J.C. Dalton, L.P. Ranum, Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum, *Neurology* 60 (2003) 657-664.
- [30] L. Machuca-Tzili, D. Brook, D. Hilton-Jones, Clinical and molecular aspects of the myotonic dystrophies: A review, *Muscle Nerve* (2005).
- [31] C.L. Liquori, K. Ricker, M.L. Moseley, J.F. Jacobsen, W. Kress, S.L. Naylor, J.W. Day, L.P. Ranum, Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9, *Science* 293 (2001) 864-867.
- [32] B. Udd, G. Meola, R. Krahe, C. Thornton, L.P. Ranum, G. Bassez, W. Kress, B. Schoser, R. Moxley, Myotonic Dystrophy DM2/PROMM and other myotonic dystrophies: 140th ENMC International Workshop with guidelines on management, *Neuromuscul Disord* (2006).
- [33] T.B. Rajavashisth, A.K. Taylor, A. Andalibi, K.L. Svenson, A.J. Lusic, Identification of a zinc finger protein that binds to the sterol regulatory element, *Science* 245 (1989) 640-643.
- [34] L. Pellizzoni, F. Lotti, B. Maras, P. Pierandrei-Amaldi, Cellular nucleic acid binding protein binds a conserved region of the 5' UTR of *Xenopus laevis* ribosomal protein mRNAs, *J Mol Biol* 267 (1997) 264-275.
- [35] K. Shimizu, W. Chen, A.M. Ashique, R. Moroi, Y.P. Li, Molecular cloning, developmental expression, promoter analysis and functional characterization of the mouse CNBP gene, *Gene* 307 (2003) 51-62.
- [36] P.S. Harper, Congenital myotonic dystrophy in Britain. I. Clinical aspects, *Arch Dis Child* 50 (1975) 505-513.
- [37] J.W. Day, L.P. Ranum, RNA pathogenesis of the myotonic dystrophies, *Neuromuscul Disord* 15 (2005) 5-16.
- [38] A. Mankodi, C.A. Thornton, Myotonic syndromes, *Curr Opin Neurol* 15 (2002) 545-552.
- [39] M.C. Koch, K. Steinmeyer, C. Lorenz, K. Ricker, F. Wolf, M. Otto, B. Zoll, F. Lehmann-Horn, K.H. Grzeschik, T.J. Jentsch, The skeletal muscle chloride channel in dominant and recessive human myotonia, *Science* 257 (1992) 797-800.
- [40] A. Vihola, G. Bassez, G. Meola, S. Zhang, H. Haapasalo, A. Paetau, E. Mancinelli, A. Rouche, J.Y. Hogrel, P. Laforet, T. Maisonobe, J.F. Pellissier, R. Krahe, B. Eymard, B. Udd, Histopathological differences of myotonic dystrophy type 1 (DM1) and PROMM/DM2, *Neurology* 60 (2003) 1854-1857.
- [41] P.S. Harper, Myotonic dystrophy, 3rd ed., W. B. Saunders, London, 2001.
- [42] C. Tsilfidis, A.E. MacKenzie, G. Mettler, J. Barcelo, R.G. Korneluk, Correlation between CTG trinucleotide repeat length and frequency of severe congenital myotonic dystrophy, *Nat Genet* 1 (1992) 192-195.
- [43] R.G. Pearse, C.J. Howeler, Neonatal form of dystrophina myotonica. Five cases in preterm babies and a review of earlier reports, *Arch Dis Child* 54 (1979) 331-338.
- [44] D. Furling, T. Lam le, O. Agbulut, G.S. Butler-Browne, G.E. Morris, Changes in myotonic dystrophy protein kinase levels and muscle development in congenital myotonic dystrophy, *Am J Pathol* 162 (2003) 1001-1009.
- [45] H.B. Sarnat, S.W. Silbert, Maturation arrest of fetal muscle in neonatal myotonic dystrophy. A pathologic study of four cases, *Arch Neurol* 33 (1976) 466-474.
- [46] M.C. Koch, T. Grimm, H.G. Harley, P.S. Harper, Genetic risks for children of women with myotonic dystrophy, *Am J Hum Genet* 48 (1991) 1084-1091.
- [47] S.J. Tapscott, C.A. Thornton, Biomedicine. Reconstructing myotonic dystrophy, *Science* 293 (2001) 816-817.
- [48] P. Carango, J.E. Noble, H.G. Marks, V.L. Funanage, Absence of myotonic dystrophy protein kinase (DMPK) mRNA as a result of a triplet repeat expansion in myotonic dystrophy, *Genomics* 18 (1993) 340-348.
- [49] Y.H. Fu, D.L. Friedman, S. Richards, J.A. Pearlman, R.A. Gibbs, A. Pizzuti, T. Ashizawa, M.B. Perryman, G. Scarlato, R.G. Fenwick, Jr., et al., Decreased expression of myotonin-

- protein kinase messenger RNA and protein in adult form of myotonic dystrophy, *Science* 260 (1993) 235-238.
- [50] G. Novelli, M. Gennarelli, G. Zelano, A. Pizzuti, C. Fattorini, C.T. Caskey, B. Dallapiccola, Failure in detecting mRNA transcripts from the mutated allele in myotonic dystrophy muscle, *Biochem Mol Biol Int* 29 (1993) 291-297.
- [51] G. Jansen, P.J. Groenen, D. Bachner, P.H. Jap, M. Coerwinkel, F. Oerlemans, W. van den Broek, B. Gohlsch, D. Pette, J.J. Plomp, P.C. Molenaar, M.G. Nederhoff, C.J. van Echteld, M. Dekker, A. Berns, H. Hameister, B. Wieringa, Abnormal myotonic dystrophy protein kinase levels produce only mild myopathy in mice, *Nat Genet* 13 (1996) 316-324.
- [52] S. Reddy, D.B. Smith, M.M. Rich, J.M. Leferovich, P. Reilly, B.M. Davis, K. Tran, H. Rayburn, R. Bronson, D. Cros, R.J. Balice-Gordon, D. Housman, Mice lacking the myotonic dystrophy protein kinase develop a late onset progressive myopathy, *Nat Genet* 13 (1996) 325-335.
- [53] C.I. Berul, C.T. Maguire, M.J. Aronovitz, J. Greenwood, C. Miller, J. Gehrmann, D. Housman, M.E. Mendelsohn, S. Reddy, DMPK dosage alterations result in atrioventricular conduction abnormalities in a mouse myotonic dystrophy model, *J Clin Invest* 103 (1999) R1-7.
- [54] H.C. Lee, M.K. Patel, D.J. Mistry, Q. Wang, S. Reddy, J.R. Moorman, J.P. Mounsey, Abnormal Na channel gating in murine cardiac myocytes deficient in myotonic dystrophy protein kinase, *Physiol Genomics* 12 (2003) 147-157.
- [55] G.S. Pall, K.J. Johnson, G.L. Smith, Abnormal contractile activity and calcium cycling in cardiac myocytes isolated from DMPK knockout mice, *Physiol Genomics* 13 (2003) 139-146.
- [56] K.L. Taneja, M. McCurrach, M. Schalling, D. Housman, R.H. Singer, Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells and tissues, *J Cell Biol* 128 (1995) 995-1002.
- [57] B.M. Davis, M.E. McCurrach, K.L. Taneja, R.H. Singer, D.E. Housman, Expansion of a CUG trinucleotide repeat in the 3' untranslated region of myotonic dystrophy protein kinase transcripts results in nuclear retention of transcripts, *Proc Natl Acad Sci U S A* 94 (1997) 7388-7393.
- [58] J. Wang, E. Pegoraro, E. Menegazzo, M. Gennarelli, R.C. Hoop, C. Angelini, E.P. Hoffman, Myotonic dystrophy: evidence for a possible dominant-negative RNA mutation, *Hum Mol Genet* 4 (1995) 599-606.
- [59] L.T. Timchenko, N.A. Timchenko, C.T. Caskey, R. Roberts, Novel proteins with binding specificity for DNA CTG repeats and RNA CUG repeats: implications for myotonic dystrophy, *Hum Mol Genet* 5 (1996) 115-121.
- [60] L.T. Timchenko, J.W. Miller, N.A. Timchenko, D.R. DeVore, K.V. Datar, L. Lin, R. Roberts, C.T. Caskey, M.S. Swanson, Identification of a (CUG)_n triplet repeat RNA-binding protein and its expression in myotonic dystrophy, *Nucleic Acids Res* 24 (1996) 4407-4414.
- [61] A.N. Ladd, N. Charlet, T.A. Cooper, The CELF family of RNA binding proteins is implicated in cell-specific and developmentally regulated alternative splicing, *Mol Cell Biol* 21 (2001) 1285-1296.
- [62] A.V. Philips, L.T. Timchenko, T.A. Cooper, Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy, *Science* 280 (1998) 737-741.
- [63] S. Michalowski, J.W. Miller, C.R. Urbinati, M. Paliouras, M.S. Swanson, J. Griffith, Visualization of double-stranded RNAs from the myotonic dystrophy protein kinase gene and interactions with CUG-binding protein, *Nucleic Acids Res* 27 (1999) 3534-3542.
- [64] M. Fardaei, K. Larkin, J.D. Brook, M.G. Hamshere, In vivo co-localisation of MBNL protein with DMPK expanded-repeat transcripts, *Nucleic Acids Res* 29 (2001) 2766-2771.
- [65] N.A. Timchenko, Z.J. Cai, A.L. Welm, S. Reddy, T. Ashizawa, L.T. Timchenko, RNA CUG repeats sequester CUGBP1 and alter protein levels and activity of CUGBP1, *J Biol Chem* 276 (2001) 7820-7826.

- [66] B.N. Charlet, R.S. Savkur, G. Singh, A.V. Philips, E.A. Grice, T.A. Cooper, Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing, *Mol Cell* 10 (2002) 45-53.
- [67] R.S. Savkur, A.V. Philips, T.A. Cooper, Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy, *Nat Genet* 29 (2001) 40-47.
- [68] A. Mankodi, E. Logigian, L. Callahan, C. McClain, R. White, D. Henderson, M. Krym, C.A. Thornton, Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat, *Science* 289 (2000) 1769-1773.
- [69] H. Seznec, O. Agbulut, N. Sergeant, C. Savouret, A. Ghestem, N. Tabti, J.C. Willer, L. Ourth, C. Duros, E. Brisson, C. Fouquet, G. Butler-Browne, A. Delacourte, C. Junien, G. Gourdon, Mice transgenic for the human myotonic dystrophy region with expanded CTG repeats display muscular and brain abnormalities, *Hum Mol Genet* 10 (2001) 2717-2726.
- [70] J.W. Miller, C.R. Urbinati, P. Teng-Umuay, M.G. Stenberg, B.J. Byrne, C.A. Thornton, M.S. Swanson, Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy, *Embo J* 19 (2000) 4439-4448.
- [71] M. Fardaei, M.T. Rogers, H.M. Thorpe, K. Larkin, M.G. Hamshere, P.S. Harper, J.D. Brook, Three proteins, MBNL, MBLL and MBXL, co-localize in vivo with nuclear foci of expanded-repeat transcripts in DM1 and DM2 cells, *Hum Mol Genet* 11 (2002) 805-814.
- [72] R. Artero, A. Prokop, N. Paricio, G. Begemann, I. Pueyo, M. Mlodzik, M. Perez-Alonso, M.K. Baylies, The muscleblind gene participates in the organization of Z-bands and epidermal attachments of *Drosophila* muscles and is regulated by Dmef2, *Dev Biol* 195 (1998) 131-143.
- [73] G. Begemann, N. Paricio, R. Artero, I. Kiss, M. Perez-Alonso, M. Mlodzik, muscleblind, a gene required for photoreceptor differentiation in *Drosophila*, encodes novel nuclear Cys3His-type zinc-finger-containing proteins, *Development* 124 (1997) 4321-4331.
- [74] R.N. Kanadia, K.A. Johnstone, A. Mankodi, C. Lungu, C.A. Thornton, D. Esson, A.M. Timmers, W.W. Hauswirth, M.S. Swanson, A muscleblind knockout model for myotonic dystrophy, *Science* 302 (2003) 1978-1980.
- [75] T.H. Ho, B.N. Charlet, M.G. Poulos, G. Singh, M.S. Swanson, T.A. Cooper, Muscleblind proteins regulate alternative splicing, *Embo J* 23 (2004) 3103-3112.
- [76] W. Dansithong, S. Paul, L. Comai, S. Reddy, MBNL1 is the primary determinant of focus formation and aberrant insulin receptor splicing in DM1, *J Biol Chem* 280 (2005) 5773-5780.
- [77] T.H. Ho, D. Bundman, D.L. Armstrong, T.A. Cooper, Transgenic mice expressing CUG-BP1 reproduce splicing mis-regulation observed in myotonic dystrophy, *Hum Mol Genet* 14 (2005) 1539-1547.
- [78] N.A. Timchenko, R. Patel, P. Iakova, Z.J. Cai, L. Quan, L.T. Timchenko, Overexpression of CUG triplet repeat-binding protein, CUGBP1, in mice inhibits myogenesis, *J Biol Chem* 279 (2004) 13129-13139.
- [79] T.H. Ho, R.S. Savkur, M.G. Poulos, M.A. Mancini, M.S. Swanson, T.A. Cooper, Colocalization of muscleblind with RNA foci is separable from mis-regulation of alternative splicing in myotonic dystrophy, *J Cell Sci* 118 (2005) 2923-2933.
- [80] Y.H. Wang, J. Griffith, Expanded CTG triplet blocks from the myotonic dystrophy gene create the strongest known natural nucleosome positioning elements, *Genomics* 25 (1995) 570-573.
- [81] Y.H. Wang, S. Amirhaeri, S. Kang, R.D. Wells, J.D. Griffith, Preferential nucleosome assembly at DNA triplet repeats from the myotonic dystrophy gene, *Science* 265 (1994) 669-671.
- [82] A.D. Otten, S.J. Tapscott, Triplet repeat expansion in myotonic dystrophy alters the adjacent chromatin structure, *Proc Natl Acad Sci U S A* 92 (1995) 5465-5469.

- [83] G.N. Filippova, C.P. Thienes, B.H. Penn, D.H. Cho, Y.J. Hu, J.M. Moore, T.R. Klesert, V.V. Lobanenkov, S.J. Tapscott, CTCF-binding sites flank CTG/CAG repeats and form a methylation-sensitive insulator at the DM1 locus, *Nat Genet* 28 (2001) 335-343.
- [84] T.R. Klesert, A.D. Otten, T.D. Bird, S.J. Tapscott, Trinucleotide repeat expansion at the myotonic dystrophy locus reduces expression of DMAHP, *Nat Genet* 16 (1997) 402-406.
- [85] C.A. Thornton, J.P. Wymer, Z. Simmons, C. McClain, R.T. Moxley, 3rd, Expansion of the myotonic dystrophy CTG repeat reduces expression of the flanking DMAHP gene, *Nat Genet* 16 (1997) 407-409.
- [86] T.R. Klesert, D.H. Cho, J.I. Clark, J. Maylie, J. Adelman, L. Snider, E.C. Yuen, P. Soriano, S.J. Tapscott, Mice deficient in Six5 develop cataracts: implications for myotonic dystrophy, *Nat Genet* 25 (2000) 105-109.
- [87] P.S. Sarkar, B. Appukuttan, J. Han, Y. Ito, C. Ai, W. Tsai, Y. Chai, J.T. Stout, S. Reddy, Heterozygous loss of Six5 in mice is sufficient to cause ocular cataracts, *Nat Genet* 25 (2000) 110-114.
- [88] H. Wakimoto, C.T. Maguire, M.C. Sherwood, M.M. Vargas, P.S. Sarkar, J. Han, S. Reddy, C.I. Berul, Characterization of cardiac conduction system abnormalities in mice with targeted disruption of Six5 gene, *J Interv Card Electrophysiol* 7 (2002) 127-135.
- [89] K.E. Personius, J. Nautiyal, S. Reddy, Myotonia and muscle contractile properties in mice with SIX5 deficiency, *Muscle Nerve* 31 (2005) 503-505.
- [90] M. Alwazzan, E. Newman, M.G. Hamshere, J.D. Brook, Myotonic dystrophy is associated with a reduced level of RNA from the DMWD allele adjacent to the expanded repeat, *Hum Mol Genet* 8 (1999) 1491-1497.
- [91] A. Mankodi, C.R. Urbinati, Q.P. Yuan, R.T. Moxley, V. Sansone, M. Krym, D. Henderson, M. Schalling, M.S. Swanson, C.A. Thornton, Muscleblind localizes to nuclear foci of aberrant RNA in myotonic dystrophy types 1 and 2, *Hum Mol Genet* 10 (2001) 2165-2170.
- [92] A. Mankodi, M.P. Takahashi, H. Jiang, C.L. Beck, W.J. Bowers, R.T. Moxley, S.C. Cannon, C.A. Thornton, Expanded CUG repeats trigger aberrant splicing of CIC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy, *Mol Cell* 10 (2002) 35-44.
- [93] R.S. Savkur, A.V. Philips, T.A. Cooper, J.C. Dalton, M.L. Moseley, L.P. Ranum, J.W. Day, Insulin receptor splicing alteration in myotonic dystrophy type 2, *Am J Hum Genet* 74 (2004) 1309-1313.
- [94] J.D. Amack, M.S. Mahadevan, Myogenic defects in myotonic dystrophy, *Dev Biol* 265 (2004) 294-301.
- [95] R.A. Martienssen, Maintenance of heterochromatin by RNA interference of tandem repeats, *Nat Genet* 35 (2003) 213-214.
- [96] I.M. Hall, G.D. Shankaranarayana, K. Noma, N. Ayoub, A. Cohen, S.I. Grewal, Establishment and maintenance of a heterochromatin domain, *Science* 297 (2002) 2232-2237.
- [97] B.J. Reinhart, D.P. Bartel, Small RNAs correspond to centromere heterochromatic repeats, *Science* 297 (2002) 1831.
- [98] T.A. Volpe, C. Kidner, I.M. Hall, G. Teng, S.I. Grewal, R.A. Martienssen, Regulation of heterochromatic silencing and histone H3 lysine-9 methylation by RNAi, *Science* 297 (2002) 1833-1837.
- [99] J.D. Amack, M.S. Mahadevan, The myotonic dystrophy expanded CUG repeat tract is necessary but not sufficient to disrupt C2C12 myoblast differentiation, *Hum Mol Genet* 10 (2001) 1879-1887.
- [100] L.A. Sabourin, K. Tamai, M.A. Narang, R.G. Korneluk, Overexpression of 3'-untranslated region of the myotonic dystrophy kinase cDNA inhibits myoblast differentiation in vitro, *J Biol Chem* 272 (1997) 29626-29635.


- [101] C.J. Storbeck, S. Drmanic, K. Daniel, J.D. Waring, F.R. Jirik, D.J. Parry, N. Ahmed, L.A. Sabourin, J.E. Ikeda, R.G. Korneluk, Inhibition of myogenesis in transgenic mice expressing the human DMPK 3'-UTR, *Hum Mol Genet* 13 (2004) 589-600.
- [102] R. Ohlsson, R. Renkawitz, V. Lobanenko, CTCF is a uniquely versatile transcription regulator linked to epigenetics and disease, *Trends Genet* 17 (2001) 520-527.
- [103] P. Steinbach, D. Glaser, W. Vogel, M. Wolf, S. Schwemmler, The DMPK gene of severely affected myotonic dystrophy patients is hypermethylated proximal to the largely expanded CTG repeat, *Am J Hum Genet* 62 (1998) 278-285.
- [104] D.H. Cho, C.P. Thienes, S.E. Mahoney, E. Analau, G.N. Filippova, S.J. Tapscott, Antisense transcription and heterochromatin at the DM1 CTG repeats are constrained by CTCF, *Mol Cell* 20 (2005) 483-489.
- [105] E. Bernstein, C.D. Allis, RNA meets chromatin, *Genes Dev* 19 (2005) 1635-1655.
- [106] D.F. O'Coilain, C. Perez-Terzic, S. Reyes, G.C. Kane, A. Behfar, D.M. Hodgson, J.A. Strommen, X.K. Liu, W. van den Broek, D.G. Wansink, B. Wieringa, A. Terzic, Transgenic overexpression of human DMPK accumulates into hypertrophic cardiomyopathy, myotonic myopathy and hypotension traits of myotonic dystrophy, *Hum Mol Genet* 13 (2004) 2505-2518.
- [107] A. Buj-Bello, D. Furling, H. Tronchere, J. Laporte, T. Lerouge, G.S. Butler-Browne, J.L. Mandel, Muscle-specific alternative splicing of myotubularin-related 1 gene is impaired in DM1 muscle cells, *Hum Mol Genet* 11 (2002) 2297-2307.
- [108] H. Jiang, A. Mankodi, M.S. Swanson, R.T. Moxley, C.A. Thornton, Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons, *Hum Mol Genet* 13 (2004) 3079-3088.
- [109] M.A. Langlois, C. Boniface, G. Wang, J. Alluin, P.M. Salvaterra, J. Puymirat, J.J. Rossi, N.S. Lee, Cytoplasmic and nuclear retained DMPK mRNAs are targets for RNA interference in myotonic dystrophy cells, *J Biol Chem* 280 (2005) 16949-16954.
- [110] D.H. Kim, M.A. Langlois, K.B. Lee, A.D. Riggs, J. Puymirat, J.J. Rossi, HnRNP H inhibits nuclear export of mRNA containing expanded CUG repeats and a distal branch point sequence, *Nucleic Acids Res* 33 (2005) 3866-3874.
- [111] D. Furling, G. Doucet, M.A. Langlois, L. Timchenko, E. Belanger, L. Cossette, J. Puymirat, Viral vector producing antisense RNA restores myotonic dystrophy myoblast functions, *Gene Ther* 10 (2003) 795-802.
- [112] M.A. Langlois, N.S. Lee, J.J. Rossi, J. Puymirat, Hammerhead ribozyme-mediated destruction of nuclear foci in myotonic dystrophy myoblasts, *Mol Ther* 7 (2003) 670-680.
- [113] H. Furuya, N. Shinnoh, Y. Ohyagi, K. Ikezoe, H. Kikuchi, M. Osoegawa, Y. Fukumaki, Y. Nakabeppu, T. Hayashi, J. Kira, Some flavonoids and DHEA-S prevent the cis-effect of expanded CTG repeats in a stable PC12 cell transformant, *Biochem Pharmacol* 69 (2005) 503-516.
- [114] A. Ebralidze, Y. Wang, V. Petkova, K. Ebralidze, R.P. Junghans, RNA leaching of transcription factors disrupts transcription in myotonic dystrophy, *Science* 303 (2004) 383-387.
- [115] Y. Kino, D. Mori, Y. Oma, Y. Takeshita, N. Sasagawa, S. Ishiura, Muscleblind protein, MBNL1/EXP, binds specifically to CHHG repeats, *Hum Mol Genet* 13 (2004) 495-507.
- [116] T. Kimura, M. Nakamori, J.D. Lueck, P. Pouliquin, F. Aoike, H. Fujimura, R.T. Dirksen, M.P. Takahashi, A.F. Dulhunty, S. Sakoda, Altered mRNA splicing of the skeletal muscle ryanodine receptor and sarcoplasmic/endoplasmic reticulum Ca²⁺-ATPase in myotonic dystrophy type 1, *Hum Mol Genet* 14 (2005) 2189-2200.

Figure 1. Clinical features of myotonic dystrophy. Myotonic dystrophy type 1 (DM1) and type 2 (DM2) share several hallmark clinical traits affecting the muscle, eye, heart, brain and endocrine systems. DM1-specific features include a distal pattern of muscle weakness and atrophy at disease onset, congenital DM1 with associated symptoms of mental retardation, hypotonia and facial diplegia, as well as gastrointestinal tract problems (congenital and late onset) that are notably absent in reports of DM2. Clinical symptoms unique to DM2 include a pronounced proximal distribution of muscle weakness and atrophy at disease onset and hypertrophy of calf muscles.

Figure 2. RNA toxic gain-of-function model for myotonic dystrophy. Myotonic dystrophy is associated with expansions in either CTG repeats in the 3'UTR of *DMPK* or with CCTG repeats in intron 1 of *ZNF9*. RNA transcripts likely form double-stranded hairpin structures from the extended tracts of CUG or CCUG repeats, to which MBNL proteins prefer to bind [70, 115]. MBNL proteins co-localize with the ribonuclear inclusions formed by mutant RNA [91]. It is not clear whether nuclear sequestration of MBNL directly leads to a significant decrease in normal MBNL activity, or whether expanded CUG/CCUG RNA signals an alternate pathway to MBNL functional inhibition [79]. CUG-BP1 levels are increased in DM1 cells [65, 67], independent of MBNL protein regulation [76]. Increased CUG-BP activity and/or loss of MBNL function may lead to aberrant gene splicing events associated with DM1 and DM2 as shown. So far, it has been shown that myotonia and insulin resistance can be attributed to splicing defects in chloride channel 1 (ClC-1) and insulin receptor (INSR), respectively, in DM1 and DM2 cells [66, 67]. Other identified splicing alterations in DM tissues are as follows: TNNT2, cardiac troponin T [62]; TNNT3, skeletal muscle troponin T [74]; MAPT, microtubule-associated protein tau [108]; APP, amyloid beta precursor protein [108]; NMDAR1, *N*-methyl-D-aspartate receptor 1 [108]; RyR1, ryanodine receptor 1 [116]; SERCA, sarcoplasmic/endoplasmic reticulum Ca²⁺-ATPase [116]; MTMR1, myotubularin-related 1 gene [77, 107].

Figure 1

Clinical Features of Myotonic Dystrophy



*symptoms present in DM2, but more prominent in DM1

Figure 2

